Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Soligenix, Inc. (SNGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its 10-K and 10-Q reports, 8-K current reports and registration statements such as Form S-1. Soligenix describes itself in these documents as a Delaware-incorporated, late-stage biopharmaceutical company listed on The Nasdaq Capital Market, focused on rare-disease therapeutics and biodefense-oriented vaccines through its Specialized BioTherapeutics and Public Health Solutions segments.
For this issuer, Form 10-K and Form 10-Q are central for understanding segment results, research and development spending, risk factors and details on programs like HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, dusquetide-based candidates SGX942 and SGX945, and vaccine initiatives such as RiVax®, filovirus vaccines and CiVax™ leveraging the ThermoVax® platform. These periodic reports also describe government grant and contract funding from agencies including NIAID, DTRA and BARDA that support the Public Health Solutions segment.
Form 8-K current reports are particularly relevant for SNGX because they capture material events such as clinical milestones, FDA orphan drug designations, equity offerings and Nasdaq listing status updates. For example, 8-K filings in 2025 document an orphan drug designation for dusquetide in Behçet's Disease, a Nasdaq notice regarding stockholders’ equity compliance and a subsequent notice of regained compliance, the approval of a 2025 equity incentive plan, and the closing of a public offering that extended the company’s cash runway.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as new financing terms, changes in capital structure, or updates to clinical and regulatory strategy. Users can also track insider transaction reports on Form 4, along with registration statements like Form S-1 related to public offerings and warrant issuances, to better understand dilution, capital-raising activities and governance matters for Soligenix.
Christopher J. Schaber, who serves as Chairman, CEO and President of Soligenix, Inc. (SNGX), reported an insider purchase on 10/02/2025. The filing shows he acquired 15,132 shares of the company’s common stock at a weighted-average price of $1.3217 per share; the report notes trades executed at prices ranging from $1.32 to $1.325. After the transaction, the filing reports he beneficially owned 15,511 shares (direct). The Form 4 was signed on 10/03/2025 and includes an undertaking to provide trade-level details on request.
Soligenix Schedule 13G summary: This filing reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC (the Reporting Persons) each may be deemed to beneficially own 446,408 shares of Soligenix common stock, representing 4.99% of the class as of the close of business on October 1, 2025. The filing explains ownership arises from warrants issued under a Securities Purchase Agreement dated September 25, 2025 and details earlier potential beneficial ownership figures tied to issuance and exercise of three warrants and a contemplated issuance of 425,000 shares to Intracoastal at closing. Blocker provisions in the warrants limit exercise to remain at or below specified ownership thresholds.
Soligenix, Inc. entered into a securities purchase agreement for a public equity offering consisting of common stock, pre-funded warrants and common warrants. The company agreed to sell 4,064,080 shares of common stock, pre-funded warrants to purchase 1,491,480 shares, and common warrants to purchase 5,555,560 shares, sold in units. Each common stock unit with a common warrant was priced at $1.35, and each pre-funded warrant unit with a common warrant at $1.349, with the common warrants exercisable at $1.35 per share for five years.
The offering closed with aggregate gross proceeds of approximately $7.5 million before fees and expenses, which the company states extends its cash runway through the end of 2026. Soligenix plans to use the net proceeds for research, development and commercialization activities and general corporate and working capital purposes. The company agreed to a 60-day lock-up on new issuances and a one-year restriction on variable rate transactions, and also reduced the exercise price of certain existing warrants to $1.35 and aligned their expiration with the new warrants.
Soligenix, Inc. is offering 4,064,080 shares of common stock, pre-funded warrants to purchase 1,491,480 shares and common warrants to purchase 5,555,560 shares at a public offering price of $1.35 per share (common warrants exercise price $1.35; pre-funded warrants exercise price $0.001). Net proceeds are estimated at approximately $6.8 million to fund R&D, commercialization activities and general corporate purposes. The offering is intended to address Nasdaq noncompliance after receiving a notice for failing to meet the $2.5 million stockholders' equity listing requirement; Soligenix estimates needing at least $3.4 million net proceeds to regain compliance. The prospectus discloses a going concern warning, limited cash runway into Q4 2025 absent new funding, no minimum offering close and potential dilution from existing warrants, options and future issuances.
Soligenix, Inc. is a clinical-stage biopharma with two operating segments: Specialized BioTherapeutics and Public Health Solutions. The company has no approved products and reported for the six months ended June 30, 2025 a net loss of $5,653,244 and used $4,588,835 of cash in operating activities, with working capital of $1,691,345. As of June 30, 2025 the company had 3,504,950 shares issued and outstanding and significant potential dilution from 1,467,581 warrants, 300,467 options (112,332 vested) and 5,929,412 shares available under the 2025 Equity Incentive Plan. Recent financing activity included issuance of 780,620 ATM shares at a weighted average price of $1.84 for gross proceeds of ~$1.44M. Management expects to pursue additional equity, grant/contract funding, partnerships, or other strategic transactions but states uncertainty about obtaining sufficient capital. The filing discloses an auditor going-concern opinion and substantial risks tied to government funding, clinical/regulatory outcomes, third-party manufacturing, and market acceptance.
Soligenix, Inc. reported that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation to dusquetide, the active ingredient in its drug candidate SGX945, for the treatment of Behçet’s Disease. This decision follows review of recent Phase 2a clinical results that showed biological efficacy and safety in patients with Behçet’s Disease.
The company highlighted that this regulatory milestone is based on early-stage clinical data and cautioned that forward-looking statements are subject to significant risks and uncertainties described in its periodic SEC reports.
Soligenix, Inc. reported that it received a notice from Nasdaq on August 15, 2025 stating the company no longer meets the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market. In its Form 10-Q for the quarter ended June 30, 2025, Soligenix reported stockholders’ equity of $1,828,951, below this threshold, although this figure does not include gross proceeds of approximately $1,439,300 from sales under its At-The-Market facility on July 1, 2025.
The company also does not satisfy Nasdaq’s alternative continued listing standards based on market value or net income. The notice does not immediately affect trading, and the stock continues to trade on Nasdaq under the symbol SNGX. Soligenix has 45 calendar days, until September 29, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance. If the plan is not accepted or compliance is not regained, the company’s common stock could become subject to delisting, with the possibility of an appeal to a Nasdaq Hearings Panel.
Form 4 filing reveals that Anthony Gregg Lapointe, Director of Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This grant represents standard director compensation and indicates continued board engagement. The 10-year option term provides long-term alignment with shareholder interests.
Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.
The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:
- September 20, 2025
- December 20, 2025
- March 20, 2026
- June 20, 2026
This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.